Genetic polymorphisms in the Toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer

Human Immunology

Volumn 75, Issue 8, 2014, Pages 808-815

  Castaño Rodríguez, Natalia ^a   Kaakoush, Nadeem O ^a   Pardo, Aryce L ^b   Goh, Khean Lee ^c   Fock, Kwong Ming ^d   Mitchell, Hazel M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Helicobacter pylori; Polymorphism; Stomach neoplasms; Toll like receptors

Indexed keywords

CD14 ANTIGEN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; ACUTE PHASE PROTEIN; CARRIER PROTEIN; INTERLEUKIN 1 RECEPTOR; LIPOPOLYSACCHARIDE-BINDING PROTEIN; LY96 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN MD 2; TIRAP PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

AGED; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HUMAN; INFECTION RISK; LBP GENE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MD 2 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH CANCER; TIRAP GENE; CHINA; COMPLICATION; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; HELICOBACTER PYLORI; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; STOMACH TUMOR;

ACUTE-PHASE PROTEINS; AGED; ANTIGENS, CD14; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHINA; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOCYTE ANTIGEN 96; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84905127342     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.06.001     Document Type: Article

References (57)

1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France, International Agency for Research on Cancer, 2013.
2. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006, 19:449-490.
3. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988, 48:3554-3560.
6. Hornef M.W., Bogdan C. The role of epithelial Toll-like receptor expression in host defense and microbial tolerance. J Endotoxin Res 2005, 11:124-128.
7. Chochi K., Ichikura T., Kinoshita M., Majima T., Shinomiya N., Tsujimoto H., et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-Toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 2008, 14:2909-2917.
8. Smith M.F., Mitchell A., Li G., Ding S., Fitzmaurice A.M., Ryan K., et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003, 278:32552-32560.
9. Yokota S., Okabayashi T., Rehli M., Fujii N., Amano K. Helicobacter pylori lipopolysaccharides upregulate Toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun 2010, 78:468-476.
10. Tsan M.F. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006, 16:32-37.
11. Kono K., Ressing M.E., Brandt R.M., Melief C.J., Potkul R.K., Andersson B., et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996, 2:1825-1828.
12. Schmielau J., Nalesnik M.A., Finn O.J. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001, 7:933s-939s.
13. Macarthur M., Hold G.L., El-Omar E.M. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004, 286:G515-G520.
14. Yang C.A., Scheibenbogen C., Bauer S., Kleinle C., Wex T., Bornschein J., et al. A frequent Toll-like receptor 1 gene polymorphism affects NK- and T-cell IFN-gamma production and is associated with Helicobacter pylori-induced gastric disease. Helicobacter 2013, 18:13-21.
15. Castano-Rodriguez N., Kaakoush N.O., Goh K.L., Fock K.M., Mitchell H.M. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS ONE 2013, 8:e60327.
16. Zeng H.M., Pan K.F., Zhang Y., Zhang L., Ma J.L., Zhou T. The correlation between polymorphisms of Toll-like receptor 2 and Toll-like receptor 9 and susceptibility to gastric cancer. Zhonghua Yu Fang Yi Xue Za Zhi 2011, 45:588-592.
17. Santini D., Angeletti S., Ruzzo A., Dicuonzo G., Galluzzo S., Vincenzi B., et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008, 154:360-364.
18. Zeng H.M., Pan K.F., Zhang Y., Zhang L., Ma J.L., Zhou T., et al. Genetic variants of Toll-like receptor 2 and 5, Helicobacter pylori infection, and risk of gastric cancer and its precursors in a chinese population. Cancer Epidemiol Biomarkers Prev 2011, 20:2594-2602.
19. Wang X., Xue L., Yang Y., Xu L., Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS ONE 2013, 8:e65731.
20. Talley N.J., Stanghellini V., Heading R.C., Koch K.L., Malagelada J.R., Tytgat G.N. Functional gastroduodenal disorders. Gut 1999, 45(Suppl. 2):II37-II42.
21. Mitchell H., English D.R., Elliott F., Gengos M., Barrett J.H., Giles G.G., et al. Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer. Aliment Pharmacol Ther 2008, 28:903-910.
22. Schmidt H.M., Ha D.M., Taylor E.F., Kovach Z., Goh K.L., Fock K.M., et al. Variation in human genetic polymorphisms, their association with Helicobacter pylori acquisition and gastric cancer in a multi-ethnic country. J Gastroenterol Hepatol 2011, 26:1725-1732.
23. Jurinke C., van den Boom D., Cantor C.R., Koster H. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol 2002, 77:57-74.
24. Oeth P.B.M., Park C., Kosman D., del Mistro G., van den Boom D., Jurinke C. iPLEX™ assay: increased plexing efficiency and flexibility for MassARRAY system through single base primer extension with mass-modified terminators. Sequenom 2005, 12.
25. Hazbon M.H., Alland D. Hairpin primers for simplified single-nucleotide polymorphism analysis of Mycobacterium tuberculosis and other organisms. J Clin Microbiol 2004, 42:1236-1242.
26. Chan W.F., Maharjan R.P., Reeves P.R., Sintchenko V., Gilbert G.L., Lan R. Rapid and accurate typing of Bordetella pertussis targeting genes encoding acellular vaccine antigens using real time PCR and high resolution melt analysis. J Microbiol Methods 2009, 77:326-329.
27. Slatkin M., Excoffier L. Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm. Heredity 1996, 76(Pt 4):377-383.
28. Excoffier L., Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995, 12:921-927.
29. Excoffier L., Laval G., Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 2005, 1:47-50.
30. Wroblewski L.E., Peek R.M., Wilson K.T. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010, 23:713-739.
31. Palli D., Cipriani F., Decarli A., Galli M., Saieva C., Fraumeni J.F., et al. Reproductive history and gastric cancer among post-menopausal women. Int J Cancer 1994, 56:812-815.
32. Sipponen P., Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002, 5:213-219.
33. Fock K.M. Helicobacter pylori infection-current status in Singapore. Ann Acad Med Singapore 1997, 26:637-641.
34. Zhao D., Sun T., Zhang X., Guo Y., Yu D., Yang M., et al. Role of CD14 promoter polymorphisms in Helicobacter pylori infection-related gastric carcinoma. Clin Cancer Res 2007, 13:2362-2368.
35. Rallabhandi P., Bell J., Boukhvalova M.S., Medvedev A., Lorenz E., Arditi M., et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006, 177:322-332.
36. Kutikhin A.G. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol 2011, 72:193-206.
37. Hishida A., Matsuo K., Goto Y., Naito M., Wakai K., Tajima K., et al. Combined effect of miR-146a rs2910164 G/C polymorphism and Toll-like receptor 4 +3725 G/C polymorphism on the risk of severe gastric atrophy in Japanese. Dig Dis Sci 2011, 56:1131-1137.
38. Kupcinskas J., Wex T., Bornschein J., Selgrad M., Leja M., Juozaityte E., et al. Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 2011, 12:112.
39. Sato K., Yoshimura A., Kaneko T., Ukai T., Ozaki Y., Nakamura H., et al. A single nucleotide polymorphism in 3'-untranslated region contributes to the regulation of Toll-like receptor 4 translation. J Biol Chem 2012, 287:25163-25172.
40. Huang L., Yuan K., Liu J., Ren X., Dong X., Tian W., et al. Polymorphisms of the TLR4 gene and risk of gastric cancer. Gene 2014, 537:46-50.
41. Zhang K., Zhou B., Wang Y., Rao L., Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer 2013, 49:946-954.
42. Chen R., Davydov E.V., Sirota M., Butte A.J. Non-synonymous and synonymous coding SNPs show similar likelihood and effect size of human disease association. PLoS ONE 2010, 5:e13574.
43. Liu J., Radler D., Illi S., Klucker E., Turan E., von Mutius E., et al. TLR2 polymorphisms influence neonatal regulatory T cells depending on maternal atopy. Allergy 2011, 66:1020-1029.
44. Rad R., Brenner L., Bauer S., Schwendy S., Layland L., da Costa C.P., et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 2006, 131:525-537.
45. Jang T.J. The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol Res Pract 2010, 206:34-38.
46. Kindlund B., Sjoling A., Hansson M., Edebo A., Hansson L.E., Sjovall H., et al. FOXP3-expressing CD4(+) T-cell numbers increase in areas of duodenal gastric metaplasia and are associated to CD4(+) T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter 2009, 14:192-201.
47. Mayerle J., den Hoed C.M., Schurmann C., Stolk L., Homuth G., Peters M.J., et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 2013, 309:1912-1920.
48. Queiroz D.M., Saraiva I.E., Rocha G.A., Rocha A.M., Gomes L.I., Melo F.F., et al. IL2-330G polymorphic allele is associated with decreased risk of Helicobacter pylori infection in adulthood. Microbes Infect 2009, 11:980-987.
49. Zambon C.F., Basso D., Navaglia F., Belluco C., Falda A., Fogar P., et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 2005, 29:141-152.
50. Chen Y.C., Hsiao C.C., Chen C.J., Chin C.H., Liu S.F., Wu C.C., et al. Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts. BMC Med Genet 2010, 11:17.
51. Hawn T.R., Dunstan S.J., Thwaites G.E., Simmons C.P., Thuong N.T., Lan N.T., et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006, 194:1127-1134.
52. Purdue M.P., Lan Q., Wang S.S., Kricker A., Menashe I., Zheng T.Z., et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009, 30:275-281.
53. Rajaraman P., Brenner A.V., Butler M.A., Wang S.S., Pfeiffer R.M., Ruder A.M., et al. Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev 2009, 18:1651-1658.
54. Nischalke H.D., Coenen M., Berger C., Aldenhoff K., Muller T., Berg T., et al. The Toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2012, 130:1470-1475.
55. Castiblanco J., Varela D.C., Castano-Rodriguez N., Rojas-Villarraga A., Hincapie M.E., Anaya J.M. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008, 8:541-544.
56. Gu W., Shan Y.A., Zhou J., Jiang D.P., Zhang L., Du D.Y., et al. Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann Surg 2007, 246:151-158.
57. Chien J.W., Boeckh M.J., Hansen J.A., Clark J.G. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008, 111:2462-2469.